Morishima Yasuo, Kashiwase Koichi, Matsuo Keitaro, Azuma Fumihiro, Morishima Satoko, Onizuka Makoto, Yabe Toshio, Murata Makoto, Doki Noriko, Eto Tetsuya, Mori Takehiko, Miyamura Koichi, Sao Hiroshi, Ichinohe Tatsuo, Saji Hiroo, Kato Shunichi, Atsuta Yoshiko, Kawa Keisei, Kodera Yoshihisa, Sasazuki Takehiko
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;
Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan;
Blood. 2015 Feb 12;125(7):1189-97. doi: 10.1182/blood-2014-10-604785. Epub 2014 Dec 17.
We hypothesized that the compatibility of each HLA loci between donor and patient induced divergent transplant-related immunologic responses, which attributed to the individualized manifestation of clinical outcomes. Here, we analyzed 7898 Japanese pairs transplanted with T-cell-replete marrow from an unrelated donor with complete HLA allele typing data. Multivariable competing risk regression analyses were conducted to evaluate the relative risk (RR) of clinical outcomes after transplantation. A significant RR of HLA allele mismatch compared with match was seen with HLA-A, -B, -C, and -DPB1 for grade III-IV acute graft-versus-host disease (GVHD), and HLA-C for chronic GVHD. Of note, only HLA-C and HLA-DPB1 mismatch reduced leukemia relapse, and this graft-versus-leukemia effect of HLA-DPB1 was independent of chronic GVHD. HLA-DRB1 and HLA-DQB1 double (DRB1_DQB1) mismatch was revealed to be a significant RR for acute GVHD and mortality, whereas single mismatch was not. Thus, the number of HLA-A, -B, -C, -DPB1, and DRB1_DQB1 mismatches showed a clear-cut risk difference for acute GVHD, whereas the number of mismatches for HLA-A, -B, -C, and DRB1_DQB1 showed the same for mortality. In conclusion, we determined the biological response to HLA locus mismatch in transplant-related immunologic events, and provide a rationale for use of a personalized algorithm for unrelated donor selection.
我们假设供体与患者之间每个HLA基因座的相容性会引发不同的移植相关免疫反应,这归因于临床结果的个体化表现。在此,我们分析了7898对接受来自无关供体的富含T细胞骨髓移植的日本患者对,这些患者具有完整的HLA等位基因分型数据。进行多变量竞争风险回归分析以评估移植后临床结果的相对风险(RR)。对于III-IV级急性移植物抗宿主病(GVHD),HLA-A、-B、-C和-DPB1的HLA等位基因错配与匹配相比具有显著的RR,对于慢性GVHD,HLA-C具有显著RR。值得注意的是,只有HLA-C和HLA-DPB1错配可降低白血病复发,并且HLA-DPB1的这种移植物抗白血病作用独立于慢性GVHD。HLA-DRB1和HLA-DQB1双重(DRB1_DQB1)错配被证明是急性GVHD和死亡率的显著RR,而单一错配则不是。因此,HLA-A、-B、-C、-DPB1和DRB1_DQB1错配的数量在急性GVHD方面显示出明显的风险差异,而HLA-A、-B、-C和DRB1_DQB1错配的数量在死亡率方面显示相同。总之,我们确定了移植相关免疫事件中对HLA基因座错配的生物学反应,并为使用个性化算法选择无关供体提供了理论依据。